MARKET

NXTC

NXTC

Nextcure
NASDAQ
12.34
-0.40
-3.10%
After Hours: 12.34 0 0.00% 16:10 12/05 EST
OPEN
12.40
PREV CLOSE
12.73
HIGH
12.81
LOW
12.10
VOLUME
24.99K
TURNOVER
--
52 WEEK HIGH
15.74
52 WEEK LOW
2.688
MARKET CAP
41.79M
P/E (TTM)
-0.5100
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NXTC last week (1124-1128)?
Weekly Report · 6d ago
NextCure files to sell 2.52M shares of common stock for holders
TipRanks · 11/26 21:05
Nextcure Files For Offering Of Up To 2.52M Common Shares By Selling Stockholders
Benzinga · 11/26 21:05
NEXTCURE INC FILES FOR OFFERING OF UP TO 2.52 MLN SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING
Reuters · 11/26 21:02
U.S. RESEARCH ROUNDUP-Air Products, Hanover Insurance, Kinsale Capital
Reuters · 11/25 07:29
Piper Sandler Keeps Their Buy Rating on NextCure (NXTC)
TipRanks · 11/24 11:56
Weekly Report: what happened at NXTC last week (1117-1121)?
Weekly Report · 11/24 10:25
NextCure Inc. to Present at Piper Sandler 37th Annual Healthcare Conference
Reuters · 11/20 13:00
More
About NXTC
NextCure, Inc. is a clinical-stage biopharmaceutical company that is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of action, including antibody-drug conjugates (ADC). It focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.

Webull offers NextCure Inc stock information, including NASDAQ: NXTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NXTC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NXTC stock methods without spending real money on the virtual paper trading platform.